» Articles » PMID: 25333018

Thrombogenic Potential of Transcatheter Aortic Valve Implantation with Trivial Paravalvular Leakage

Overview
Journal Ann Transl Med
Date 2014 Oct 22
PMID 25333018
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Significant paravalvular leakage after transcatheter aortic valve implantation (TAVI) correlates with increased morbidity and mortality, but adverse consequences of trivial paravalvular leakage have stimulated few investigations. Using a unique method distinctly different from other diagnostic approaches, we previously reported elevated backflow velocities of short duration (transients) in mechanical valve closure. In this study, similar transients were found in a transcatheter valve paravalvular leakage avatar.

Methods: Paravalvular leakage rate (zero to 58 mL/second) and aortic valve incompetence (volumetric back flow/forward flow; zero to 32%) were made adjustable using a mock transcatheter aortic valve device and tested in quasi-steady and pulsatile flow test systems. Projected dynamic valve area (PDVA) from the back illuminated mock transcatheter aortic valve device was measured and regional backflow velocities were derived by dividing volumetric flow rate by the PDVA over the open and closing valve phase and the total closed valve area derived from backflow leakage.

Results: Aortic incompetence from 1-32% generated negative backflow transients from 8 to 267 meters/second, a range not dissimilar to that measured in mechanical valves with zero paravalvular leakage. Optimal paravalvular leakage was identified; not too small generating high backflow transients, not too large considering volume overload and cardiac energy loss caused by defective valve behavior and fluid motion.

Conclusions: Thrombogenic potential of transcatheter aortic valves with trivial aortic incompetence and high magnitude regional backflow velocity transients was comparable to mechanical valves. This may have relevance to stroke rate, asymptomatic microembolic episodes and indications for anticoagulation therapy after transcatheter valve insertion.

Citing Articles

Aortic valve replacement in sheep with a novel trileaflet mechanical heart valve prosthesis without anticoagulation.

Schaller T, Scharfschwerdt M, Schubert K, Prinz C, Lembke U, Sievers H JTCVS Open. 2022; 7:76-88.

PMID: 36003713 PMC: 9390555. DOI: 10.1016/j.xjon.2021.05.011.


Biomechanics of Transcatheter Aortic Valve Implant.

Nappi F, Avtaar Singh S, Nappi P, Fiore A Bioengineering (Basel). 2022; 9(7).

PMID: 35877350 PMC: 9312295. DOI: 10.3390/bioengineering9070299.


Clinical predictors and sequelae of computed tomography defined leaflet thrombosis following transcatheter aortic valve replacement at medium-term follow-up.

Rashid H, Michail M, Ihdayhid A, Dowling C, Khav N, Tan S Heart Vessels. 2021; 36(9):1374-1383.

PMID: 33660057 DOI: 10.1007/s00380-021-01803-4.


Predictors and Biomarkers of Subclinical Leaflet Thrombosis after Transcatheter Aortic Valve Implantation.

Pieniak K, Jedrzejczyk S, Domaszk O, Grodecki K, Rymuza B, Huczek Z J Clin Med. 2020; 9(11).

PMID: 33233321 PMC: 7700436. DOI: 10.3390/jcm9113742.


New Insights into Valve Hemodynamics.

Marom G, Einav S Rambam Maimonides Med J. 2020; 11(2).

PMID: 32374253 PMC: 7202448. DOI: 10.5041/RMMJ.10400.


References
1.
Lynch Jr D, Dantzler D, Robbins M, Zhao D . Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013; 35(4):476-82. DOI: 10.1007/s11239-013-0886-z. View

2.
Pibarot P, Dumesnil J . Doppler echocardiographic evaluation of prosthetic valve function. Heart. 2011; 98(1):69-78. DOI: 10.1136/heartjnl-2011-300351. View

3.
Vasa-Nicotera M, Sinning J, Chin D, Lim T, Spyt T, Jilaihawi H . Impact of paravalvular leakage on outcome in patients after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2012; 5(8):858-65. DOI: 10.1016/j.jcin.2012.04.011. View

4.
Astarci P, Etienne P, Raucent B, Bollen X, Tranduy K, Glineur D . Transcatheter resection of the native aortic valve prior to endovalve implantation - A rational approach to reduce TAVI-induced complications. Ann Cardiothorac Surg. 2013; 1(2):224-30. PMC: 3741734. DOI: 10.3978/j.issn.2225-319X.2012.06.15. View

5.
Bluestein D, Chandran K, Manning K . Towards non-thrombogenic performance of blood recirculating devices. Ann Biomed Eng. 2010; 38(3):1236-56. PMC: 2862578. DOI: 10.1007/s10439-010-9905-9. View